Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
NCT04477785 · View on ClinicalTrials.gov ↗
Study Summary
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Conditions Studied
Study Locations (20)
Arizona
- Barrow Neurological Institute — Phoenix
- Mayo Foundation for Medical Education and Research — Scottsdale
- Banner Research Institute — Sun City
California
- University of California San Diego — La Jolla
- Keck School of Medicine of USC — Los Angeles
- University of California, San Francisco — San Francisco
Florida
- Parkinson's Disease& Movement Disorder Center of Boca Raton — Boca Raton
- University of Florida — Gainesville
- University of South Florida — Tampa
Massachusetts
- Boston University — Boston
- Massachusetts General Hospital — Boston
Alabama
- University of Alabama at Birmingham — Birmingham
Colorado
- University of Colorado Anschutz Medical Campus — Aurora
Connecticut
- Institute For Neurodegenerative Disorders — New Haven
Georgia
- Emory University School of Medicine — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,500 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2033-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04477785
The ClinicalTrials.gov registry entry for NCT04477785 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 4,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael J. Fox Foundation for Parkinson's Research, which has 9 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04477785 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Arizona, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04477785 about?
NCT04477785 is a clinical study titled "PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort". The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest ...
What is the current status of trial NCT04477785?
This trial is currently recruiting. The enrollment target is 4,500 participants. The study started on 2020-07-01. Estimated completion is 2033-12.
What conditions does trial NCT04477785 study?
This clinical trial studies the following conditions: Parkinson Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT04477785?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 9 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04477785 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.